RE: Bingo!15 Aug 2023 08:01
On 20 April 2023, Vela announced that the Company entered into a put option agreement to give the Company the right, but not the obligation ("the Option"), to sell its economic interest in the commercialisation of the Covid-19 application of AZD1656 for a total consideration of £4.0 million. The Option was granted by Conduit Pharmaceuticals Limited ("Conduit") and its prospective parent company, Murphy, a Company listed on NASDAQ.
If the outcome from the meeting on the 7th September 2023 is approved then consider Vela banking £4 million…only 3 weeks left for boom time :-))